Signature Nucleotide Polymorphisms at Positions 64 and 65 in Reverse Transcriptase Favor the Selection of the K65R Resistance Mutation in HIV-1 Subtype C

Journal of Infectious Diseases

Volumn 200, Issue 8, 2009, Pages 1202-1206

  Invernizzi, Cédric F ^a,b,c   Coutsinos, Dimitrios ^a,b,c   Oliveira, Maureen ^a   Moisi, Daniela ^a   Brenner, Bluma G ^a,b,c   Wainberg, Mark A ^a,b,c,d  

^a MCGILL UNIVERSITY   (Canada)

^b Departments of Medicine   (Switzerland)

^c MCGILL UNIVERSITY   (Canada)

^d Spiez Laboratory Spiez   (Switzerland)

Author keywords

[No Author keywords available]

Indexed keywords

ABACAVIR; APRICITABINE; DIDANOSINE; EMTRICITABINE; LAMIVUDINE; RNA DIRECTED DNA POLYMERASE; RNA DIRECTED DNA POLYMERASE INHIBITOR; STAVUDINE; TENOFOVIR;

ANTIVIRAL RESISTANCE; ARTICLE; CONTROLLED STUDY; DRUG SELECTIVITY; GENETIC POLYMORPHISM; GENETIC SELECTION; HUMAN; HUMAN CELL; HUMAN IMMUNODEFICIENCY VIRUS 1; NONHUMAN; PRIORITY JOURNAL; VIRUS MUTATION; WILD TYPE;

ANTI-HIV AGENTS; CELLS; DRUG RESISTANCE, VIRAL; HIV REVERSE TRANSCRIPTASE; HIV-1; HUMANS; MUTATION; POLYMORPHISM, GENETIC; SELECTION (GENETICS); TIME FACTORS;

EID: 70349428513     PISSN: 00221899     EISSN: None     Source Type: Journal    
DOI: 10.1086/605894     Document Type: Article

References (15)

1. Brenner B.G. Oliveira M. Doualla-Bell F. Moisi D.D. Ntemgwa M. Frankel F. Essex M. Wainberg M.A. HIV-1 subtype C viruses rapidly develop K65R resistance to tenofovir in cell culture AIDS 2006 20 9 F9-F13 DOI 10.1097/01.aids. 0000232228.88511.0b, PII 0000203020060612000001 1. Brenner BG, Oliveira M, Doualla-Bell F, et al. HIV-1 subtype C viruses rapidly develop K65R resistance to tenofovir in cell culture. AIDS 2006;20:F9-13. (Pubitemid 44030369)
2. Kantor R. Katzenstein D.A. Efron B. Carvalho A.P. Wynhoven B. Cane P. Clarke J. Sirivichayakul S. Soares M.A. Snoeck J. Pillay C. Rudich H. Rodrigues R. Holguin A. Ariyoshi K. Bouzas M.B. Cahn P. Sugiura W. Soriano V. Brigido L.F. Grossman Z. Morris L. Vandamme A.-M. Tanuri A. Phanuphak P. Weber J.N. Pillay D. Harrigan P.R. Camacho R. Schapiro J.M. Shafer R.W. Impact of HIV-1 subtype and antiretroviral therapy on protease and reverse transcriptase genotype: Results of a global collaboration PLoS Medicine 2005 2 4 0325-0337 http://medicine.plosjournals.org/archive/1549-1676/2/4/pdf/10.1371-journal.pmed. 0020112-L.pdf DOI 10.1371/journal.pmed.0020112, e112 2. Kantor R, Katzenstein DA, Efron B, et al. Impact of HIV-1 subtype and antiretroviral therapy on protease and reverse transcriptase genotype: results of a global collaboration. PLoS Med 2005;2:e112. (Pubitemid 40721078)
3. Kantor R. Impact of HIV-1 pol diversity on drug resistance and its clinical implications Current Opinion in Infectious Diseases 2006 19 6 594-606 DOI 10.1097/QCO.0b013e3280109122, PII 0000143220061200000012 3. Kantor R. Impact of HIV-1 pol diversity on drug resistance and its clinical implications. Curr Opin Infect Dis 2006; 19:594-606. (Pubitemid 44665467)
4. Miller M.D. Margot N. McColl D. Cheng A.K. K65R development among subtype C HIV-1-infected patients in tenofovir DF clinical trials [8] AIDS 2007 21 2 265-266 DOI 10.1097/QAD.0b013e32801199ee, PII 0000203020070111000030 4. Miller MD, Margot N, McColl D, Cheng AK. K65R development among subtype C HIV-1 -infected patients in tenofovir DF clinical trials. AIDS 2007;21:265-266 (Pubitemid 46036948)
5. Brenner BG. Resistance and viral subtypes: how important are the differences and why do they occur? Curr Opin HIV AIDS 2007; 2:94-102.
6. Doualla-Bell F. Avalos A. Brenner B. Gaolathe T. Mine M. Gaseitsiwe S. Oliveira M. Moisi D. Ndwapi N. Moffat H. Essex M. Wainberg M.A. High prevalence of the K65R mutation in human immunodeficiency virus type 1 subtype C isolates from infected patients in Botswana treated with didanosine-based regimens Antimicrobial Agents and Chemotherapy 2006 50 12 4182-4185 DOI 10.1128/AAC.00714-06 6. Doualla-Bell F, Avalos A, Brenner B, et al. High prevalence of the K65R mutation in human immunodeficiency virus type 1 subtype C isolates from infected patients in Botswana treated with didanosine-based regimens. Antimicrob Agents Chemother 2006;50:4182-4185 (Pubitemid 44865165)
7. Wallis C, Bell C, Boulme R, et al. Emerging ART drug resistance in subtype C: experience from the 2 clinics in Johannesburg, South Africa [poster 661]. In: Program and abstracts of the 14th Conference on Retroviruses and Opportunistic Infections (Los Angeles). Alexandria, VA: Conference on Retroviruses and Opportunistic Infections, 2007.
8. Hosseinipour MC, van Oosterhout JJ, Weigel R, et al. The public health approach to identify antiretroviral therapy failure: high-level nucleoside reverse transcriptase inhibitor resistance among Malawians failing firstline antiretroviral therapy. AIDS 2009;23:1127-34.
9. Orrell C, Walensky RP, Losina E, Pitt J, Freedberg KA, Wood R. HIV type-1 clade C resistance genotypes in treatment-naive patients and after first virological failure in a large community antiretroviral therapy programme. Antivir Ther 2009; 14:523-531
10. Xu HT, Martinez-Cajas JL, Ntemgwa ML, et al. Effects of the K65R and K65R/M184V reverse transcriptase mutations in subtype C HIV on enzyme function and drug resistance. Retrovirology 2009; 6:14.
11. Coutsinos D, Invernizzi CF, Xu H, et al. Template usage is responsible for the preferential acquisition of the K65R reverse transcriptase mutation in subtype C variants of human immunodeficiency virus type 1. J Virol 2009;83:2029-2033
12. Schinazi R.F. Lloyd R.M. Jr. Ramanathan C.S. Taylor E.W. Antiviral drug resistance mutations in human immunodeficiency virus type 1 reverse transcriptase occur in specific RNA structural regions Antimicrobial Agents and Chemotherapy 1994 38 2 268-274 12. Schinazi RF, Lloyd RM Jr, Ramanathan CS, Taylor EW Antiviral drug resistance mutations in human immunodeficiency virus type 1 reverse transcriptase occur in specific RNA structural regions. Antimicrob Agents Chemother 1994;38:268-274 (Pubitemid 24054246)
13. Cong M.-E. Heneine W. Garcia-Lerma J.G. The fitness cost of mutations associated with human immunodeficiency virus type 1 drug resistance is modulated by mutational interactions Journal of Virology 2007 81 6 3037-3041 DOI 10.1128/JVI.02712-06 13. Cong ME, Heneine W, Garcia-Lerma JG. The fitness cost of mutations associated with human immunodeficiency virus type 1 drug resistance is modulated by mutational interactions. J Virol 2007;81:3037-3041 (Pubitemid 46447070)
14. Parikh U.M. Zelina S. Sluis-Cremer N. Mellors J.W. Molecular mechanisms of bidirectional antagonism between K65R and thymidine analog mutations in HIV-1 reverse transcriptase AIDS 2007 21 11 1405-1414 DOI 10.1097/QAD. 0b013e3281ac229b, PII 0000203020070711000003 14. Parikh UM, Zelina S, Sluis-Cremer N, Mellors JW Molecular mechanisms of bidirectional antagonism between K65R and thymidine analog mutations in HIV-1 reverse transcriptase. AIDS 2007; 21:1405-1414 (Pubitemid 46988000)
15. Brenner B. Turner D. Oliveira M. Moisi D. Detorio M. Carobene M. Marlink R.G. Schapiro J. Roger M. Wainberg M.A. A V106M mutation in HIV-1 clade C viruses exposed to efavirenz confers cross-resistance to non-nucleoside reverse transcriptase inhibitors AIDS 2003 17 1 F1-F5 DOI 10.1097/00002030-200301030- 00001 15. Brenner B, Turner D, Oliveira M, et al. A V106M mutation in HIV1 clade C viruses exposed to efavirenz confers cross-resistance to nonnucleoside reverse transcriptase inhibitors. AIDS 2003; 17:F1-5. (Pubitemid 36106291)